215 related articles for article (PubMed ID: 30153191)
21. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
22. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
23. Dalbavancin approved for acute skin infections.
Traynor K
Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
[No Abstract] [Full Text] [Related]
24. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
25. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection.
Gupta AK; Foley KA; Abramovits W; Rosen T
Skinmed; 2014; 12(6):366-9. PubMed ID: 25823083
[No Abstract] [Full Text] [Related]
26. New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE.
Szűcs Z; Ostorházi E; Kicsák M; Nagy L; Borbás A; Herczegh P
J Antibiot (Tokyo); 2019 Jul; 72(7):524-534. PubMed ID: 30874609
[TBL] [Abstract][Full Text] [Related]
27. Oritavancin: first global approval.
Markham A
Drugs; 2014 Oct; 74(15):1823-8. PubMed ID: 25239268
[TBL] [Abstract][Full Text] [Related]
28. Current trends in the real-life use of dalbavancin: report of a study panel.
Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
[TBL] [Abstract][Full Text] [Related]
29. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
Belley A; Lalonde Seguin D; Arhin F; Moeck G
Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
[TBL] [Abstract][Full Text] [Related]
30. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Van Bambeke F
Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
[TBL] [Abstract][Full Text] [Related]
31. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
Oliva A; Carbonara S; Cianci V; Crapis M; Di Domenico EG; Falcone M; Galardo G; Durante-Mangoni E; Venditti M
Expert Rev Anti Infect Ther; 2023; 21(7):703-721. PubMed ID: 37227028
[TBL] [Abstract][Full Text] [Related]
32. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
[TBL] [Abstract][Full Text] [Related]
33. Oritavancin versus oral antibiotics for treatment of skin and skin structure infections in the emergency department.
Sacdal JPA; Cheon E; Stilwell AM; Acquisto NM; Treu CN
Am J Emerg Med; 2022 Oct; 60():223-224. PubMed ID: 35835659
[No Abstract] [Full Text] [Related]
34. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
35. Dalbavancin or oritavancin for skin infections.
Cormican M
N Engl J Med; 2014 Sep; 371(12):1161. PubMed ID: 25229925
[No Abstract] [Full Text] [Related]
36. Dalbavancin.
Anderson VR; Keating GM
Drugs; 2008; 68(5):639-48; discussion 649-51. PubMed ID: 18370443
[TBL] [Abstract][Full Text] [Related]
37. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
Crotty MP; Krekel T; Burnham CA; Ritchie DJ
J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
[TBL] [Abstract][Full Text] [Related]
39. Dalbavancin or oritavancin for skin infections.
Corey GR; Jiang H; Moeck G
N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251
[No Abstract] [Full Text] [Related]
40. Dalbavancin or oritavancin for skin infections.
Baang J; Fisher S
N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]